Clotting, immune system, and venous thrombosis in lung adenocarcinoma patients: a prospective study

Cancer Invest. 2009 Dec;27(10):989-97. doi: 10.3109/07357900903124464.

Abstract

Thrombosis is highly prevalent in cancer patients, being accepted as a bad prognosis marker. The importance of various mechanisms involved in the thrombophilic state of lung cancer patients is not well understood. In this prospective study, involving 109 unselected patients with lung adenocarcinoma, thrombosis was present in 24% of patients and affected survival in a bivariable model. However, in a multivariable evaluation, considering all the factors under study, only LAC and IgM anti-beta(2) GP I modified thrombosis risk, whereas in a Kaplan-Meyer regression model, thrombosis, IL-6, LAC, factor VIII, and IgM anti-beta(2) GP I interfered with patient's survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / complications*
  • Adenocarcinoma / immunology
  • Adenocarcinoma / mortality
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Blood Coagulation*
  • Cytokines / blood*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms / blood
  • Lung Neoplasms / complications*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Venous Thrombosis / blood
  • Venous Thrombosis / etiology*
  • Venous Thrombosis / immunology
  • Venous Thrombosis / mortality

Substances

  • Autoantibodies
  • Biomarkers
  • Cytokines